{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 18 of 129', 'Subjects randomised to tralokinumab in the initial treatment period and with a', 'clinical response at Week 16 will be re-randomised 1:1 to one of the following', 'Q2W maintenance regimens stratified by region and IGA response at Week 16', '(IGA 0/1 or IGA >1):', 'Tralokinumab 300 mg Q2W.', 'Alternating dose administrations tralokinumab 300 mg and placebo', '(tralokinumab Q4W).', 'Subjects randomised to placebo in the initial treatment period and with a', 'clinical response at Week 16 will receive placebo Q2W in the continuation', 'treatment period. Non-responders at Week 16 in the tralokinumab and placebo', 'groups will receive tralokinumab 300 mg Q2W.', 'The primary endpoints are assessed at Week 16, and the final efficacy', 'assessment will be conducted at Week 32.', 'Starting on Day 0 (baseline), all subjects will be allowed to initiate treatment', 'once daily with a supplied TCS on lesional skin and continue as needed', 'throughout the treatment period. TCS use will be monitored throughout the', 'trial.', 'All subjects will use an emollient twice daily (or more, as needed) for at least', '14 days before randomisation and will continue this treatment throughout the', 'trial (including safety follow-up). On lesional skin, emollients should only be', 'applied at a time where TCS is not applied; on TCS-untreated areas, the', 'emollients may be applied at all times.', 'Main assessments', 'Efficacy: investigator assessments', 'IGA.', 'EASI.', 'SCORAD.', 'AD flares.', 'Efficacy: subject assessments', 'Six patient-reported outcomes (PROs) will be assessed daily using an electronic', 'diary: Eczema-related Sleep NRS, Worst Daily Pruritus NRS, Average Daily', 'Pruritus NRS, Patient Days of Topical Treatment Use, Patient Global', 'Impression of Bother (PGI-B), and Patient Global Impression of Severity', '(PGI-S).', 'Four PROs will be completed by the subjects at the site during trial visits:', 'Patient Oriented Eczema Measure (POEM), DLQI, EuroQoL 5-Dimension', 'Health Questionnaire 5 Level (EQ-5D-5L), and Hospital Anxiety and', 'Depression Scale (HADS).', 'Safety assessments', 'Vital signs, physical examination, electrocardiograms, laboratory testing,', 'pharmacokinetics, anti-drug antibodies, and adverse event reporting.', 'Main criteria for', 'Age 18 and above.', 'inclusion', 'Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria', 'for AD.', 'History of AD for >1 year.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 19 of 129', 'Subjects who have a recent history of inadequate response to treatment', 'with topical medications.', 'AD involvement of >10% body surface area at screening and baseline.', 'An EASI score of >12 at screening and 16 at baseline.', 'An IGA score of >3 at screening and at baseline.', 'A Worst Daily Pruritus NRS average score of >4 during the week prior', 'to baseline.', 'Stable dose of emollient twice daily (or more, as needed) for at least', '14 days before randomisation.', 'Main criteria for', 'Subjects for whom TCSs are medically inadvisable e.g., due to', 'exclusion', 'important side effects or safety risks in the opinion of the investigator.', 'Active dermatologic conditions that may confound the diagnosis of', 'AD.', 'Use of tanning beds or phototherapy within 6 weeks prior to', 'randomisation.', 'Treatment with systemic immunosuppressive/immunomodulating', 'drugs and/or systemic corticosteroid within 4 weeks prior to', 'randomisation.', 'Treatment with TCS, TCI, or topical phosphodiesterase 4 (PDE-4)', 'inhibitor within 2 weeks prior to randomisation.', 'Receipt of any marketed biological therapy (i.e. immunoglobulin, anti-', 'immunoglobulin E) including dupilumab or investigational biologic', 'agents.', 'Active skin infection within 1 week prior to randomisation.', 'Clinically significant infection within 4 weeks prior to randomisation.', 'A helminth parasitic infection within 6 months prior to the date', 'informed consent is obtained.', 'Tuberculosis requiring treatment within the 12 months prior to', 'screening.', 'Known primary immunodeficiency disorder.', 'Investigational', 'Tralokinumab (human recombinant IL 13 monoclonal antibody)', 'medicinal products', '150 mg/mL solution for SC injection in an accessorised pre-filled syringe,', '1.0 mL fill volume. Each kit contains 1 syringe.', 'Placebo', 'Placebo solution for SC injection in an accessorised pre-filled syringe, 1.0 mL', 'fill volume. Each kit contains 1 syringe.', 'Non-', 'TCS (Europe: Class 3 [potent]; US: Class 4 [mid-strength])', 'investigational', 'Mometasone furoate, 0.1% cream provided in kit sizes of 180-225 g every', 'medicinal product', '2 weeks.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}